Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03011541 · ClinicalTrials.gov registry record · NA
Stem Cell Ophthalmology Treatment Study II
A NA study of Glaucoma and Age-related Macular Degeneration, sponsored by MD Stem Cells.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 4
- Study locations
NCT03011541: Recruiting NA study of Glaucoma and Age-related Macular Degeneration, sponsored by MD Stem Cells.
NCT03011541 is a NA study of Glaucoma and Age-related Macular Degeneration that is actively recruiting participants, run by MD Stem Cells. The registered enrollment target is 500 participants, below the 905-participant average among 92 other Glaucoma trials with a reported enrollment target (45% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03011541, a NA study of Glaucoma and Age-related Macular Degeneration, is actively recruiting participants, sponsored by MD Stem Cells.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Primary Outcome
Best corrected visual acuity will be measured with Snellen Eye Chart and the ETDRS (Early Treatment Diabetic Retinopathy Study)Eye Chart when available at each post- procedure visit. Intervals at minimum will be first post- procedure day,then 3 months, 6 months and 12 months post-procedure day. Recommended visit 1 month post -procedure day.
Conditions Studied
Interventions
- PROCEDURE Arm 1
Study Locations (4)
Connecticut
- MD Stem Cells - Westport
Florida
- MD Stem Cells - Coral Springs
Austria
- MD Stem Cells Kobinia Med - Vienna
United Arab Emirates
- The Saudi-German Hospital - Dubai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2016-01 |
| Est. Completion | 2027-07-31 |
| Phase | NA |
What NCT03011541 shows while recruiting
NCT03011541 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 905-participant average among 92 other Glaucoma trials with a reported enrollment target (45% lower).
The record links to 10 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Arm 1 is the first listed.
NCT03011541 reports a single indexed study location in Connecticut, Florida, Austria.
Frequently Asked Questions
What is clinical trial NCT03011541 about?
NCT03011541 is a clinical study titled "Stem Cell Ophthalmology Treatment Study II". This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
What is the current status of trial NCT03011541?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2016-01. Estimated completion is 2027-07-31.
What conditions does trial NCT03011541 study?
This clinical trial studies the following conditions: Glaucoma, Age-related Macular Degeneration, Retinitis Pigmentosa, Retinal Disease, Stargardt Disease.
What interventions are being tested in trial NCT03011541?
The interventions under investigation include: Arm 1 (PROCEDURE).
Who is sponsoring clinical trial NCT03011541?
This trial is sponsored by MD Stem Cells, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03011541 being conducted?
This trial has 4 study locations across Connecticut, Florida, Austria, United Arab Emirates. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03011541's enrollment target sits among peer trials
500 12th of 92 higher than 81 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia